Clinical Trial Update: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for MRG-001, exploring immunoregulatory and regenerative therapy for COVID-19 patients, including ARDS.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• MRG-001

Snippet

Sponsor: MedRegen LLC | Conditions: COVID-19, ARDS, Human | Phase 2 | Status: UNKNOWN